美国 · SEC FORM 4
Attovia Therapeutics, Inc.
ATTO · Nasdaq · CIK 0002058707 · Healthcare · Biotechnology
内部人信号
85.1 / 100
6 位买方 · 13 条买入交易行 · $72.9M 买入总额
为什么有这个信号？
买方广度较强
买入规模较强
角色中等
近期性较低
确信度较强
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
Cluster+35.0 / 35
买入规模+24.4 / 25
角色+14.0 / 20
近期性+3.0 / 10
确信度+8.8 / 10
哪些因素限制了当前分数？
- ⚠ 角色得分低 · 买入者中职位最高的是：Other（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
- ✓ Cluster breadth is broad · 4+ insiders
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
WALSH COLINDirector
●●▼▼○○●●
Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.Other
●●▼▼○○●●
venBio Global Strategic Fund IV, L.P.TenPercentOwner
○●
Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLCTenPercentOwner
○●
SanofiTenPercentOwner
○●
FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P.TenPercentOwner
○●
● 买入▼ 卖出○ 其他
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
合资格买方6
买入集中度28%最大买方： WALSH COLIN · $20.6M
聚集买入 · 15天6 insiders峰值活动： 2026-08-05–2026-08-06
Roles in the peak window: Director, Other, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
85.1 / 100
最新留档分数
↓ -0.1 pts相对上一个留档快照
- 85.4
- 85.3
- 85.3
- 85.2
- 85.1
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
13买入
88卖出
18其他 Form 4 交易行
9SEC 申报 · 365天
买入13 qualifying P line(s) · 180 days
卖出88 sale line(s) · 仅供背景
其他18 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -28.1%
- 3M
- —
- 6M
- —
- 12M
- —
波动率与流动性
- 波动率
- 81.1%
- Beta
- —
- 平均每日成交额
- USD 7.3M
估值
- 市值
- USD 740.0M
- P/E
- —
基本面
- 利润率
- —
- ROE
- —
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,649,612
- 上期报告
- 831,090
- 日均成交量
- 553,841
- 回补天数
- 3.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | WALSH COLIN | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | WALSH COLIN | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. | 买入 (P) | Common Stock | 382,352 | USD 17.00 | USD 6,499,984 | SEC 申报 ↗ |
| 2026-08-06 | Sanofi | 买入 (P) | Common Stock | 300,000 | USD 17.00 | USD 5,100,000 | SEC 申报 ↗ |
| 2026-08-06 | Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLC | 买入 (P) | Common Stock | 600,000 | USD 17.00 | USD 10,200,000 | SEC 申报 ↗ |
| 2026-08-06 | FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P. | 买入 (P) | Common Stock | 588,235 | USD 17.00 | USD 9,999,995 | SEC 申报 ↗ |
| 2026-08-05 | WALSH COLIN | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
| 2026-08-05 | WALSH COLIN | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
Form 4 申报证据
119 transaction lines in the latest 365-day window; 119 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | WALSH COLIN | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | WALSH COLIN | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (25 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | WALSH COLIN | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | WALSH COLIN | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-06 | WALSH COLIN | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | WALSH COLIN | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 500,000 | USD 17.00 | USD 8,500,000 | SEC 申报 ↗ |
| 2026-08-06 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | C (C) | Common Stock | 2,435,632 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. | 买入 (P) | Common Stock | 382,352 | USD 17.00 | USD 6,499,984 | SEC 申报 ↗ |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. | C (C) | Common Stock | 3,799,015 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-06 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Capital, LP; KROIN DAVID | C (C) | Common Stock | 1,957,138 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-06 | Sanofi | 买入 (P) | Common Stock | 300,000 | USD 17.00 | USD 5,100,000 | SEC 申报 ↗ |
| 2026-08-06 | Sanofi | C (C) | Common Stock | 782,855 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-06 | Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLC | 买入 (P) | Common Stock | 600,000 | USD 17.00 | USD 10,200,000 | SEC 申报 ↗ |
| 2026-08-06 | Green Jeremy; Redmile Biopharma Investments III, L.P.; Redmile Group, LLC | C (C) | Common Stock | 782,854 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-06 | FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P. | 买入 (P) | Common Stock | 588,235 | USD 17.00 | USD 9,999,995 | SEC 申报 ↗ |
| 2026-08-06 | FHMLS XI, L.L.C.; FHMLS XI, L.P.; Frazier Life Sciences XI, L.P. | C (C) | Common Stock | 5,490,629 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-05 | WALSH COLIN | 卖出 (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC 申报 ↗ |
| 2026-08-05 | WALSH COLIN | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 卖出 (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC 申报 ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
| 2026-08-05 | WALSH COLIN | 卖出 (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC 申报 ↗ |
| 2026-08-05 | WALSH COLIN | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 卖出 (S) | Common Stock | 105,607 | USD 21.28 | USD 2,247,248 | SEC 申报 ↗ |
| 2026-08-05 | Broad Street Principal Investments, L.L.C.; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; GOLDMAN SACHS GROUP INC; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P. | 买入 (P) | Common Stock | 85,000 | USD 21.00 | USD 1,785,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ATTO |
| CIK | 0002058707 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 119 transaction lines from 2026-08-05 to 2026-08-06 13 P purchase lines · 88 S sale lines · 18 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.